Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Recruiting · NCT03326310 · Registry updated 2025-12-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Selumetinib and Azacitidine in High Risk Chronic Blood Cancers | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm, primary myelofibrosis | Recruiting | Phase 1 | 2025-12-29 | NCT03326310 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Chicago | 326 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The University of Chicago | Chicago | United States | 65 |